BahVideo.com
Dr William Matsui - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Dr William Matsui - Sidney Kimmel Comprehensive Cancer Center Baltimore USA | BahVideo.com
Watch Dr William Matsui - Sidney Kimmel Comprehensive Cancer Center,  Baltimore, USA

Dr William Matsui - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA

0 of 5 Stars
Dr William Matsui speaks about plasma cell biology and how this affects cancer growth. In multiple myeloma, malignant plasma cells make up the vast majority of tumour cells and are thought to be responsible for tumour growth. Dr Matsui speaks about the aims and challenges facing his work evaluating if rituximab can be used to treat multiple myeloma and looking to see if signalling pathways can be targeted to prevent cancer development.
Channel: www.ecancer.tv
Video Length: 0
Date Found: February 18, 2011
Category: Science
Date Produced:
View Count: 2
Flag
Related Videos
Prof Mathias Rummel - Klinikum der Justus-Liebig-Universität,  Giessen, Germany | BahVideo.com
www.ecancer.tv

Prof Mathias Rummel - Klinikum der Justus-Liebig-Universität, Giessen, Germany

0 of 5 Stars
March 01, 2011
Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line ...
Chair: Prof Meletios Dimopoulos - Univeristy of Athens,  Greece; Prof Hermann Einsele - Medizinische Klinik II, Wurzburg, Germany; Prof Mario Boccadoro - University of Turin, Italy; Dr Maria-Victoria | BahVideo.com
www.ecancer.tv

Chair: Prof Meletios Dimopoulos - Univeristy of Athens, Greece; Prof Hermann Einsele - Medizinische Klinik II, Wurzburg, Germany; Prof Mario Boccadoro - University of Turin, Italy; Dr Maria-Victoria

0 of 5 Stars
March 01, 2011
The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such as thalidomide, bortezomib and lenalidomide is helping clinicians achieve complete remission and ...
Prof Mathias Rummel - Klinikum der Justus-Liebig-Universität,  Giessen, Germany | BahVideo.com
www.ecancer.tv

Prof Mathias Rummel - Klinikum der Justus-Liebig-Universität, Giessen, Germany

0 of 5 Stars
March 01, 2011
Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.
Prof Antonio Palumbo - Molinette Hospital,  Turin, Italy and Prof Vincent Rajkumar - Mayo Clinic, Arizona, USA | BahVideo.com
www.ecancer.tv

Prof Antonio Palumbo - Molinette Hospital, Turin, Italy and Prof Vincent Rajkumar - Mayo Clinic, Arizona, USA

0 of 5 Stars
March 01, 2011
Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib ...
Prof Anton Hagenbeek - Academic Medical Center,  Amsterdam, Netherlands | BahVideo.com
www.ecancer.tv

Prof Anton Hagenbeek - Academic Medical Center, Amsterdam, Netherlands

0 of 5 Stars
February 23, 2011
Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular ...
: advertisement :
Featured
Content
Featuring websites that enhance the internet user’s experience.

Like
Like